Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
P. Moon, L. Boike, D. Dovala, N. J. Henning, M. Knapp, J. N. Spradlin, C. C. Ward, H. Wolleb, C. M. Zammit, D. Fuller, G. Blake, J. P. Murphy, F. Wang, Y. Lu, S. A. Moquin, , D. K. Nomura
This study identifies and optimizes potent pyrazoline-based covalent inhibitors of SARS-CoV-2 Mpro, showing activity against multiple coronaviruses.
bioRxiv · Mar 5, 2022Biochemistry
N. J. Henning, L. Boike, J. N. Spradlin, C. C. Ward, B. Belcher, S. M. Brittain, M. Hesse, D. Dovala, L. M. McGregor, J. M. McKenna, J. A. Tallarico, M. Schirle, D. K. Nomura
This paper introduces the DUBTAC platform for targeted protein stabilization by linking a covalent OTUB1 recruiter to lumacaftor, demonstrating stabilization of ΔF508-CFTR in human cells.
bioRxiv · Apr 30, 2021Biochemistry
N. J. Henning, A. G. Manford, J. N. Spradlin, S. M. Brittain, J. M. McKenna, J. A. Tallarico, M. Schirle, M. Rape, D. K. Nomura
The paper discovers a covalent ligand, EN106, that targets FEM1B for PROTAC-based protein degradation, demonstrating its utility in degrading BRD4.
bioRxiv · Apr 15, 2021Biochemistry
S. B. Biering, E. Van Dis, E. Wehri, L. H. Yamashiro, X. Nguyenla, C. Dugast-Darzacq, T. G. Graham, J. R. Stroumza, G. R. Golovkine, A. W. Roberts, D. M. Fines, J. N. Spradlin, C. C. Ward, T. Bajaj, D. Dovala, , S. A. Stanley
This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.
bioRxiv · Dec 30, 2020Microbiology
B. Tong, J. N. Spradlin, L. F. T. Novaes, E. Zhang, X. Hu, M. Moeller, S. M. Brittain, L. M. McGregor, J. M. McKenna, J. A. Tallarico, M. Schirle, T. J. Maimone, D. K. Nomura
This paper develops a PROTAC molecule, BT1, that selectively degrades BCR-ABL over c-ABL in leukemia cells using nimbolide as an E3 ligase recruiter, showing additional anti-proliferative effects.
bioRxiv · Apr 2, 2020Biochemistry
J. N. Spradlin, X. Hu, C. C. Ward, S. M. Brittain, M. D. Jones, L. Ou, M. To, A. Proudfoot, E. Ornleas, M. Woldegiorgis, J. A. Olzmann, D. E. Bussiere, J. R. Thomas, J. A. Tallarico, J. M. McKenna, , D. K. Nomura
This study identifies nimbolide's mechanism of action by showing it targets RNF114, leading to stabilization of p21 and inhibition of breast cancer cell proliferation.
bioRxiv · Apr 9, 2019Cancer Biology